British experts warn that access to new weight-loss drugs such as Mounjaro may depend more on wealth than medical need.[1][2][3] Strict NHS criteria limit the prescribing of Mounjar to only a small number of patients, while many others must pay for the drug privately.[1][2][4] To get Mounjar on the NHS, a patient must be over 18, have a BMI over 40 (or over 37.5 for Asian, black or other minority ethnicities) and have at least four of five conditions: type 2 diabetes, high blood pressure, heart disease, sleep apnea or abnormal blood fats.[1][2][3][4] Treatment involves weekly injections of 2.5 mg up to 15 mg, lasts a maximum of 2 years, and must be combined with dietary and exercise support.[3][5] Studies show that when combined with a healthy lifestyle, patients lose up to 20% of their body weight.[3] Researchers warn that such restrictions risk worsening health inequalities, especially for underdiagnosed groups.[1][2] They are calling for a fairer and more inclusive approach to prescribing before further widening disparities in care.[1]